Michael Flemmens, a scientist with over 25 years of product development, sales, and technical support experience, drives key research initiatives and provides strategic leadership in the application and commercialization of SōRSE’s technology platforms. Prior to SōRSE, he served as Director of Corporate Technology Development for Secant Group, LLC, a leader in next-generation biomaterials, structures, and medical textiles that enable restoration of the human body.
Michael has worked on a patented new cancer treatment, had a Type IV Drug Master File approved by the FDA, and received JECFA approval for a new food ingredient. He also designed the build-out of seven novel manufacturing lines and has held multiple government contracts for novel security products.